Literature DB >> 8460504

The role of the amino terminus of F1 of the Newcastle disease virus fusion protein in cleavage and fusion.

T Morrison1, C McQuain, T Sergel, L McGinnes, J Reitter.   

Abstract

Phenylalanine is the amino acid at the amino terminus of the F1 protein of all paramyxovirus fusion proteins with the exception of the avirulent strains of Newcastle disease virus, which have a leucine residue in this position (Toyoda et al. (1989) Virology 169, 273-282). To explore the role of this phenylalanine in the fusion activity of the protein, this residue, amino acid 117 in the fusion protein sequence, was changed to leucine (F117L) or to glycine (F117G) by site-specific mutagenesis while maintaining the cleavage site sequence of virulent strains of NDV. While both wild-type and the F117G protein were proteolytically cleaved and F1 was detected, the F117L protein was not cleaved. In the presence of the HN protein, both wild-type F and F117G proteins stimulated fusion, but the F117L protein was inactive in fusion. However, incubation in trypsin activated the fusion activity of the protein. Thus the phenylalanine at the amino terminus of the F1 component of the fusion protein is not required for the fusion activity of the protein. The presence of a leucine at this position blocks cleavage even though the cleavage site sequence is unchanged.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460504     DOI: 10.1006/viro.1993.1214

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Genetic characterization of the Korean LATC06 rinderpest vaccine strain.

Authors:  Jung-Yong Yeh; Chang-Hee Kwoen; Wooseog Jeong; Hye-Young Jeoung; Hee Soo Lee; Dong-Jun An
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

2.  High genetic diversity of Newcastle disease virus in poultry in West and Central Africa: cocirculation of genotype XIV and newly defined genotypes XVII and XVIII.

Authors:  Chantal J Snoeck; Ademola A Owoade; Emmanuel Couacy-Hymann; Bello R Alkali; Mbah P Okwen; Adeniyi T Adeyanju; Giscard F Komoyo; Emmanuel Nakouné; Alain Le Faou; Claude P Muller
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Effect of cleavage mutants on syncytium formation directed by the wild-type fusion protein of Newcastle disease virus.

Authors:  Z Li; T Sergel; E Razvi; T Morrison
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype.

Authors:  Sa Xiao; Madhuri Subbiah; Sachin Kumar; Roberta De Nardi; Calogero Terregino; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2010-03-04       Impact factor: 3.303

Review 5.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

6.  The amino-terminal residue of Sindbis virus glycoprotein E2 influences virus maturation, specific infectivity for BHK cells, and virulence in mice.

Authors:  H W Heidner; R E Johnston
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

8.  Experimental avian paramyxovirus serotype-3 infection in chickens and turkeys.

Authors:  Sachin Kumar; Flavia Militino Dias; Baibaswata Nayak; Peter L Collins; Siba K Samal
Journal:  Vet Res       Date:  2010-07-23       Impact factor: 3.683

9.  Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.

Authors:  G Alkhatib; J Roder; C Richardson; D Briedis; R Weinberg; D Smith; J Taylor; E Paoletti; S H Shen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.

Authors:  Raghunath Shobana; Siba K Samal; Subbiah Elankumaran
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.